Program
Anti-HER3/Anti-MUC1 Bispecific Antibody-drug Conjugate DM002
Its studies are led by Xadcera Biopharmaceutical (Suzhou).
Furthest: phase 2, since Dec 11, 20241 company-led study, 1 open or runningNext primary completion: Oct 8, 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Xadcera Biopharmaceutical (Suzhou) | 11 open or running | phase 2since Dec 11, 2024 | Dec 11, 2024 | Oct 8, 2027phase 2 · NCT06751329 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 11, 2024First study: phase 2 study in Ovarian NeoplasmsFirst studyNCT06751329 · 280 planned · United States, Australia
Ahead
- Oct 8, 2027Primary completion: phase 2 study in Ovarian NeoplasmsNCT06751329
TargetBeta
“An antibody-drug conjugate (ADC) composed of a bispecific antibody directed against the tumor associated antigens (TAAs) human epidermal growth factor receptor 3 (HER3; ErbB3) and mucin-1 (MUC1) ”NCIt, by rule
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06751329Ovarian Neoplasms · United States, Australia | 2 | Recruiting | Oct 8, 2027 | 280 |
How it is read
Names in the registry
- “DM002”, 1 entry
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.